Myelofibrosis Market to Reach USD 5.36 Billion by 2034

The Myelofibrosis market in the seven major markets is poised for strong growth, rising from USD 2,602 million in 2025 to USD 5,638 million by 2034, reflecting a CAGR of 9% during the forecast period.

In 2024, the total market size stood at approximately USD 2.2 billion, with the US leading at around USD 1.7 billion, far ahead of the EU4, UK, and Japan.

JAK inhibitors remain the cornerstone of treatment, led by JAKAFI/JAKAVI (ruxolitinib), which accounted for roughly USD 1.5 billion in 2024. Other key JAK inhibitors include INREBIC, VONJO, and OJJAARA, each with distinct mechanisms of action targeting various molecular pathways. While JAKAFI continues to dominate the market, patent expirations in 2027-2028 for Novartis and Incyte are expected to create both challenges and opportunities. To sustain its market share, Incyte is exploring combination therapies to extend JAKAFI’s clinical lifespan.

Emerging drugs such as imetelstat (a telomerase inhibitor), navtemadlin (an MDM2 inhibitor), and pelabresib (a BET inhibitor) are being developed to address unmet needs, particularly for patients unresponsive to JAK inhibitors.

Future growth will be driven by innovative therapies, especially those targeting lower-risk patients, novel first-line or combination treatments, and drugs addressing cytopenia management, which remains a significant unmet clinical need.

Key Myelofibrosis Companies include Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others.

According to DelveInsight’s latest report, “Myelofibrosis Market Insights, Epidemiology, and Market Forecast–2034,” the global Myelofibrosis market is set to experience remarkable growth over the next decade.

Growing Burden of Myelofibrosis

Myelofibrosis is a rare bone marrow disorder where abnormal blood cell production leads to scarring in the bone marrow, hindering normal blood formation. This results in anemia, fatigue, and an enlarged spleen. The disease primarily affects older adults and can either occur on its own or develop from other bone marrow disorders such as polycythemia vera or essential thrombocythemia.

In 2024, the total prevalence of myelofibrosis in the seven major markets (7MM)-the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan-was estimated at approximately 55,900 cases, a number expected to rise steadily through 2034. Within these markets, the United States accounted for the largest share, valued at USD 1,700 million, outpacing the EU4, the UK, and Japan.

The report also notes that high-risk patients formed the largest group of diagnosed cases in the U.S. in 2024. Additionally, patients aged 70 and above represented the highest age segment, with an estimated 12,100 cases in this group alone.

Key Myelofibrosis Market Drivers

The steady increase in Myelofibrosis cases is being driven by a combination of factors-aging populations, rising disease awareness, improved diagnostic methods, and the ongoing development of advanced therapies.
Key drivers include:

• Increased R&D investment focused on discovering targeted and disease-modifying therapies.
• Development of biological and immunotherapy approaches aimed at addressing unmet clinical needs.
• Expansion of treatment options beyond JAK inhibitors, targeting different mechanisms of action.

Myelofibrosis Market Outlook and Leading Therapies

Currently, JAKAFI/JAKAVI (ruxolitinib) from Incyte and Novartis remains the gold standard treatment for Myelofibrosis. In 2024, it accounted for the largest market share, valued at around USD 1,500 million in the 7MM. The demand for JAKAFI continues to grow due to its established efficacy in symptom management and spleen size reduction.

Other key Myelofibrosis marketed therapies include:

• INREBIC (fedratinib) – Bristol Myers Squibb
• XPOVIO (selinexor) – Karyopharm Therapeutics
• RYTELO (imetelstat) – Geron Corporation
• REBLOZYL (luspatercept) – Bristol Myers Squibb
• Navtemadlin (KRT-232) – Kartos Therapeutics

Myelofibrosis Emerging therapies are also poised to transform the treatment landscape. Promising Myelofibrosis drug candidates such as Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), and TP-3654 (Syntara) are in advanced clinical stages and may help address patients unresponsive to current therapies.

Key Companies Shaping the Myelofibrosis Market

A diverse group of pharmaceutical and biotechnology companies is actively engaged in developing novel treatment options. Leading Myelofibrosis market players include Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others.

Myelofibrosis companies are advancing innovative therapies such as LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, and Momelotinib. Their efforts are expected to drive robust competition and broaden the therapeutic arsenal against Myelofibrosis.

Recent Myelofibrosis Clinical Trials and Research Developments

Recent years have witnessed a surge in clinical research and late-stage trials focusing on improving treatment outcomes and addressing resistance to current JAK inhibitors:

• September 2025: Karyopharm Therapeutics Inc. announced the completion of patient enrollment in its Phase 3 SENTRY trial, evaluating selinexor plus ruxolitinib in JAK inhibitor–naïve patients with Myelofibrosis.
• November 2024: MorphoSys reported positive topline results from its MANIFEST-2 Phase III trial, which studied pelabresib in combination with Jakafi (ruxolitinib).
• October 2024: Ajax Therapeutics, Inc. dosed the first patient in a Phase 1 clinical trial of AJ1-11095, a novel Type II JAK2 inhibitor for Myelofibrosis.

These milestones underscore the growing momentum in Myelofibrosis R&D, with several therapies showing potential for disease modification and improved quality of life for patients.

Myelofibrosis Epidemiology Insights

The Myelofibrosis Market Report provides a comprehensive epidemiological analysis across the 7MM from 2020 to 2034. It highlights the total and diagnosed prevalence, disease severity distribution, and gender-based analysis.

In 2024, the total prevalence of myelofibrosis across the seven major markets (7MM) was estimated at around 55,900 cases, with numbers expected to rise steadily through 2034. Within the EU4 and the UK, Germany recorded the highest number of diagnosed cases, followed by Spain, while the UK had the lowest. In the United States, most patients were classified as high-risk, and primary myelofibrosis represented about 75% of all cases. Age-wise, the ≥70 years group accounted for the largest patient population, totaling approximately 12,100 cases in 2024. Additionally, around 60% of US myelofibrosis patients had JAK2 mutations, highlighting its significant role in disease prevalence. Myelofibrosis Drugs Uptake and Market Dynamics

 

Myelofibrosis Market Drivers:

• Rising prevalence of Myelofibrosis among aging populations
• Ongoing innovations in targeted drug development
• Expanding access to diagnostics and early detection programs

Myelofibrosis Market Barriers:

• High cost of therapy and limited reimbursement in some regions
• Side effects associated with long-term JAK inhibitor use
• Clinical challenges in managing advanced or resistant cases

Despite these challenges, industry experts remain optimistic about continued advancements, as multiple therapies progress through Phase 2 and Phase 3 trials with promising results.

Myelofibrosis Market Scope

• Study Period: 2020–2034
• Geographic Coverage: United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan
• Key Metrics: Market size, drug uptake, epidemiology segmentation, treatment trends, and pipeline analysis

The report also features competitive intelligence through SWOT, PESTLE, and Porter’s Five Forces analyses, as well as insights into market entry strategies, reimbursement landscapes, and unmet clinical needs.

Myelofibrosis Future Outlook

The Myelofibrosis market is set for robust expansion driven by increased disease awareness, technological progress in molecular diagnostics, and the entry of novel therapeutic agents. The combination of targeted therapies, JAK inhibitors, and next-generation immunotherapies will likely redefine the treatment landscape by 2034.

With multiple promising candidates in late-stage development and major pharmaceutical companies investing heavily in Myelofibrosis R&D, the market is expected to witness dynamic evolution in both therapeutic diversity and patient outcomes.

 

To explore detailed insights into Myelofibrosis epidemiology, market forecast, and emerging therapies, visit: Myelofibrosis Market Forecast